The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

FDA approves Symbravo for acute migraine relief, combining rizatriptan and meloxicam. Discover its unique benefits and fast ...

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective ...

A history of migraine, with or without aura, was a significant risk factor for open-angle glaucoma onset among a cohort of ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

For patients with migraine, the clinical benefits of propranolol, a beta-blocker medication, may extend beyond just migraine ...

A nurse has shared seven different ways you can differentiate between a headache and a migraine. There are several telltale ...

The rocker returned to the stage in a wheelchair, and later told fans the incident "does not merit so much attention" ...

The global prevalence and incidence of migraine significantly increased from 1990 to 2021, with faster growth rates predicted in men and adolescents through 2050.

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.